Gilead’s shares rise after $21 billion deal for Immunomedics By Reuters

Telegram to pay $18.5 million, return investor money to settle


© Reuters.

(Reuters) – Shares of Gilead Sciences Inc (O:) rose 3.2% on Monday, reversing their premarket losses as investors shrugged off concerns over the steep premium the U.S. drugmaker was willing to pay for Immunomedics Inc (O:).

Gilead on Sunday agreed to buy the biopharmaceutical company for $21 billion and acquire all the outstanding shares of Immunomedics for $88 per share, at a premium of about 108% over Friday’s closing price of $42.25.

The deal gives Gilead access to Immunomedics’ cancer treatment drug, Trodelvy, which was granted an accelerated approval in April by the U.S. Food and Drug administration for an aggressive and tough-to-treat type of breast cancer.

Brokerage Jefferies (NYSE:) said investors may take some time to digest the deal, but it believed the deal offered a path for Gilead to quickly move into the solid tumors market.

Brokerage Oppenheimer views the purchase price as “reasonable”, and said the cancer drug “slots neatly” in Gilead’s oncology strategy.

Earlier in the day, at least two brokerages raised concerns about the deal price.

Baird said Trodelvy should give Gilead a “nice addition” to cement its foothold in the cancer treatment sphere, but that it was “less than thrilled” about the price.

SVB Leerink expected the main push back from investors to be about the deal price, not the product or the commercial opportunity.

“Gilead’s purchase price is at a 300% premium to where Immunomedics traded at the start of the year, and more than 100% higher than where the stock had recently traded,” the brokerage said.

Gilead’s shares rose 3.3% to $67 in morning trading, after falling as much as 2% before the opening bell on Monday.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *


About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.


CONTACT US

CALL US ANYTIME